Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study

Qing-Lei Zeng,Guang-Ming Li,Fanpu Ji,Shu-Huan Ma,Guo-Fan Zhang,Jiang-Hai Xu,Wan-Bao Lin,Guang-Hua Xu,Guo-Qiang Zhang,Guo-Tao Li,Guang-Lin Cui,Na Liu,Fan-Jun Zeng,Zhi-Guo Ai,Guang-Feng Xu,Jie Liang,Min-Min Zhang,Cheng Li,Zhi-Hao Zhang,Ze-Shuai Wang,Zongfang Li,Zu-Jiang Yu
DOI: https://doi.org/10.1111/tbed.13674
IF: 4.521
2020-01-01
Transboundary and Emerging Diseases
Abstract:Currently, COVID-19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course and treatment efficacy of COVID-19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from 20 January to 8 February 2020. Clinical outcomes were followed up until 26 March 2020. The viral shedding duration, full clinical course and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID-19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS-CoV-2. In total, the median SARS-CoV-2 shedding period and clinical course were 12 (IQR: 9-17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16-24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively, and ICU patients had longer median viral shedding periods (21 [17-24] versus 11 [9-15]) and clinical courses (30 [22-33] vs. 19 [15.8-22]) than non-ICU patients (bothp < .0001). SARS-CoV-2 clearances occurred at least 2 days before fatality in 3 non-survivors. Current treatment with any anti-viral agent or combination did not present the benefit of shortening viral shedding period and clinical course (allp > .05) in real-life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current anti-viral therapies were ineffective for shortening viral shedding duration and clinical course in real-world settings. These findings expand our knowledge of the SARS-CoV-2 infection and may be helpful for management of the epidemic outbreak of COVID-19 worldwide. Further studies concerning effective anti-viral agents and vaccines are urgently needed.
What problem does this paper attempt to address?